Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1995-01-11
1997-09-23
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 31195
Patent
active
056705395
ABSTRACT:
The present invention relates to a method of remitting or attenuating the symptoms of movement disorders which can be secondary to treatment of psychiatric disorders with antipsychotic drugs mainly neuroleptics, movement disorders that arise secondary to non-neuroleptic drugs in the treating of non-psychiatric disorders or primary neurological disorders. This treatment involves administering a meal enriched with large neutral amino acids or a dietary supplement of large neutral amino acids to patients suffering from these disorders.
REFERENCES:
patent: 4100293 (1978-07-01), Walser et al.
patent: 4129652 (1978-12-01), Fuxe
patent: 4138484 (1979-02-01), Fuxe
patent: 4209531 (1980-06-01), Berry
patent: 4252822 (1981-02-01), Berry
patent: 4320146 (1982-03-01), Walser
patent: 4438144 (1984-03-01), Blackburn
patent: 4687782 (1987-08-01), Brantman
patent: 4780475 (1988-10-01), Cerra et al.
patent: 4837219 (1989-06-01), Hutterer
patent: 5006559 (1991-04-01), Askanazi et al.
patent: 5017616 (1991-05-01), Askanazi
patent: 5026721 (1991-06-01), Dudrick et al.
patent: 5028622 (1991-07-01), Plaitakis
patent: 5256669 (1993-10-01), Askanazi et al.
patent: 5256697 (1993-10-01), Miller et al.
Neuropsychopharmacology, vol. 6, No. 4, 1992, pp. 241-247.
J. Nutr., vol. 108, No. 7., 1978, pp. 1200-1206.
Metabolism, vol. 26, No. 2, 1977, pp. 207-223.
Psychopharmacol. Bull., vol. 25, No. 1, 1989, pp. 47-51.
J. Psychopharmacol, vol. 6, No. 2, 1992, pp. 278-280.
Int. J. Neurosciences, vol. 42, 1988, pp. 127-130.
Psychopharmacology, vol. 99, No. 3, 1989, pp. 299-303.
Richardson, et al., "The prevalence of tardive dyskinesia in a mentally retarded population," Psychopharmacol. Bull., 22:243-249, 1986.
Scriver, C.R., et al. "The hyperphenylalaninemias," The Metabolic Basis of Inherited Disease, edited by Scriver, et al, D. New York, NY, McGraw Hill, 1989, pp. 495-546.
Psychopharmacol. Bull., 25:47-51 (1989); "Amino acid metabolism and tardive dyskinesia vulnerability in schizophrenia".
"Preliminary Support for the Oral Administration of Valine, Isoleucine and Leucine for Phenylketouria," Developmental Medicine and Child Neurology, 27:33-39 (1985).
"Reduction of Cerebral Spinal Fluid Phenylalanine After Oral Administration of Valine, Isoleucine, and Leucine," Pediatric Research, 16:751-755 (1982).
Adibi, et al., "Branched Chain Amino and Keto Acids in Health and Disease," Basil:Karger (1984).
Van Woert, et al., Monographs in Neural Sciences, 3, 71-80, (1976).
Avanzini, et al., Monographs in Neural Sciences, 5, 142-152 (1980).
Jacobs, et al., Gilles de la Tourette Syndrome, eds. Friedhoff, A.J. and Chase, T.N., pp. 93-97, New York: Raven Press (1982).
Sandyk, R., et al., "L-tryptophan in drug-induced movement disorders with insomnia," N. Engl. J. Med. 1986, 314(19):1257.
Sandyk, R, et al., "L-tryptophan in neuroleptic-induced tardive dyskinesia," Int. J. Neurosci., 1988, 42:127-130.
Nasrallah, H.A., et al. "Serotonin precursor effects in tardive dyskinesia," Pharmacology, 1982, 77:234-235.
Jus, K., et al. "Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome," Int. J. Clin. Pharmacol. 1974, 9(2):138-145.
Lakke & Teelken, Neurology, 26, 489-493 (1976).
Seeman, P., J. Clinical Psychopharmacol., 8 (4, supp):3s-9s (1988).
Jeste, et al., Br. J. Psychiatry, 144:177-180 (1984).
Wagner, et al., J. Clinical Psychopharmacol., 2:312-314 (1982).
Kaufman, et al., Biol. Psychiatry, 21:799-812 (1986).
Tamminga, et al., Arch. Gen. Psychiatry, 36:595-598 (1979).
Thaker, et al., Arch. Gen. Psychiatry, 44:522-529 (1987).
Stahl, et al., Biol. Psychiatry, 20:888-893 (1985).
Andersson, et al., Mov. Disord., 4(1):37-46 (1989).
Thaker, et al., Biol. Psychiatry, 25:49-59 (1989).
Gunne, et al., Nature, 309:347-349 (1984).
Lohr, et al., Schizophr. Bull., 14:291-296 (1988).
Cadet, et al., Ann. NY Acad. Sci. 570:176-185 (1989).
Lu, et al., Biol. Psychiatry, 25:717-724 (1989).
Pardridge, W.M., Nutrition and the Brain, vol. 7: 199-241, New York: Raven Press (1986).
Giovannini, M., et al., "Serotonin and noradrenaline concentrations and serotonin uptake in platelets from hyperphenylalaninemic patients," J. Inherited Metab. Dis. 1988, 11:285-290.
Bjerkenstedt, L., et al. "Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls," Br. J. Psychiatry, 1985, 147:276-282.
Delgado, P.L., et al., "Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan," Arch. Gen. Psychiatry, 1990, 47:411-418.
Sloviter, R.S., et al. "Serotonergic properties of b-phenylethylamine in rats," Neuropharmacology, 1980, 19:1071-1074.
Dourish, CT, "Behavioral effects of acute and chronic b-phenylethylamine administration in the rat: evidence of the involvement of 5-hydroxytryptamine," Neuropharmacology, 1981, 20:1067-1072.
Hagenfeldt, L., et al. "Amino acids in plasma and CSF and monoamine metabolites in CSG: interrelationship in healthy subjects," J. Neurochem., 42(3):833-837, 1984.
Rao, J.L., et al. "Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects," Psychiatry Res., 34:243-257, 1990.
Gardos, et al., "The Acute Effects of a Loading Dose of Phenylalanine in Unipolar Depressed Patients With and Without Tardive Dyskinesia," Neuropsychopharmacology, 1992, vol. 6, No. 4.
Richardson, et al., Biological Psychiatry, vol. 2, "Proceedings fo the 5th World Congress of Biological Psychiatry", (Excerpta Medica), 1991, pp. 341-343.
2nd International Symposium on SEROTONIN from Cell Biology to Pharmacology and Therapeutics, Sep., 1992, Abstract Book, p. 4.
Joint Meeting of 4th International Trace Amines Conference and 5th International Amine Oxidase Workshop, Aug., 1992.
Bowers, et al., J. Clinical Psychopharmacol., 7:57-58 (1987).
Fibiger, et al., TINS, pp. 462-464 (Dec. 1984).
Stegnik, L.D., et al. Aspartame Physiology and Biochemistry, New York: Marcel Dekker, pp. 509-553 (1984).
Bremer, H.J., et al, Disturbances of Amino Acid metabolism:Clinical Chemistry and Diagnosis, Baltimore: Urban & Schwarzenberg, 1981.
Bowers et al, J. Clin Psychopharmacol, vol. 7, No. 1, Feb. 1987 pp. 57-58.
Richardson, et al., Journal of Psychopharmacology, 7(2) (1993) pp. 219-220.
Criares Theodore J.
New York State Office of Mental Health
LandOfFree
Treatment of movement disorders using large neutral amino acids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of movement disorders using large neutral amino acids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of movement disorders using large neutral amino acids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1938832